Nektar Therapeutics Gains 51.07%
Tue, Feb 10, 2026 at 07:18 PM
Nektar Therapeutics (NKTR:NASDAQ) shot up at $56, a gain of 51.1%. On Tue, Feb 10, 2026, NKTR:NASDAQ touched a New 2-Week High of $56. The stock appeared on our News Catalysts scanner on Tue, Feb 10, 2026 at 05:56 PM in the 'PUBLIC OFFERING' category. From Tue, Jan 27, 2026, the stock recorded 60.00% Up Days and 63.64% Green Days
About Nektar Therapeutics (NKTR:NASDAQ)
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company's research and development activities involve small-molecule drugs, and peptides.
Top 10 Gainers:
- Quince Therapeutics, Inc. (QNCX:NASDAQ), 305.92%
- Jiuzi Holdings, Inc. (JZXN:NASDAQ), 89.71%
- Evommune Inc. (EVMN:NYSE), 70.87%
- TuHURA Biosciences, Inc. (HURA:NASDAQ), 60.47%
- Founder Group Limited (FGL:NASDAQ), 55.96%
- Nektar Therapeutics (NKTR:NASDAQ), 51.07%
- ZW Data Action Technologies Inc. (CNET:NASDAQ), 49.99%
- SRx Health Solutions Inc. (SRXH:NYSEMKT), 45.55%
- BiomX Inc. (PHGE:NYSEMKT), 44.37%
- European Wax Center, Inc. (EWCZ:NASDAQ), 43%